Business Express is an online portal that covers the latest developments in the world of business and finance. From startups and entrepreneurship to mergers and acquisitions, Business Express provides reporting on the stories that matter most to business leaders and decision-makers.The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
2022 09 26T061355Z 2 LYNXMPEI8P05H RTROPTP 4 GSK CFO
2022 09 26T061355Z 2 LYNXMPEI8P05H RTROPTP 4 GSK CFO

GSK picks Burberry’s Brown as first female CFO


By Amna Karimi and Pushkala Aripaka

(Reuters) -GSK named luxury fashion brand Burberry’s Julie Brown as its first ever female chief financial officer on Monday to succeed Iain Mackay, as the British drugmaker sharpens focus on its core pharmaceuticals business.

Mackay, 60, will be retiring next year after serving as GSK’s finance chief for nearly four years, following an eight-year stint as group finance director at the bank HSBC.

The retirement, which has been in discussion for some time, comes after GSK’s spin off of its large consumer health business, Haleon, in July to focus on prescription drugs and vaccines.

Brown, also 60, will join GSK in April and take up the job in May. She has extensive experience in the health and pharmaceutical industry.

Investors may be surprised to see Iain Mackay’s retirement after only a few years in the role and the announcement coming only months after announcing the departure of head of R&D Hal Barron, J.P. Morgan analysts wrote in a note.

“Post the recent separation of the consumer health business, there may have been a desire to increase Healthcare experience in GSK’s management team,” they wrote.

Brown joined Burberry in 2017 from medical products maker Smith & Nephew and was a board member at Swiss drugmaker Roche until Sept. 26 when she stepped down.

She also served in several finance roles at AstraZeneca, which last year also appointed a female CFO, Aradhana Sarin.

Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!


By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.

With Emma Walmsley as GSK’s chief executive officer, Brown’s appointment also creates a rare, all-female top management at a blue-chip British company and a global pharma major.

Brown will receive an annual base salary of more than 900,000 pounds at GSK, the company said.

“Julie is a highly experienced CFO with a tremendous understanding of the biopharma sector. We also share a strong passion for people development, diversity, inclusion and sustainability,” CEO Walmsley said in a statement.

GSK has struck several multi-billion dollar deals recently under Mackay to shore up its drug pipeline after years of underperformance relative to its peers.

Investors are also wary of the potential for billions in damages that may arise from U.S. litigation over the heartburn drug Zantac which was originally marketed by a forerunner of GSK, and has been sold by several companies at different times, including Pfizer, Boehringer Ingelheim and Sanofi as well as a plethora of generic drugmakers.

In July, GSK delivered a strong second-quarter performance, boosting its full-year forecast.

Sky News first reported Brown’s appointment on Saturday.

(Reporting by Amna Karimi and Pushkala Aripaka in Bengaluru and Natalie Grover in London; Editing by Subhranshu Sahu, Louise Heavens and Ana Nicolaci da Costa)

 

Recent Post: